Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency

Area of Science:

• Biochemistry
• Lipid Metabolism
• Enzymology

Background:

• Lecithin:cholesterol acyltransferase (LCAT) deficiency causes rare genetic disorders, familial LCAT deficiency and fish-eye disease.
• These conditions are marked by severe hypoalphalipoproteinemia and lipoprotein abnormalities.
• Currently, no effective treatments exist for genetic LCAT deficiency.

Purpose of the Study:

• To investigate the therapeutic potential of recombinant human LCAT (rhLCAT) for correcting lipoprotein profiles in LCAT-deficient plasma.
• To assess the efficacy of rhLCAT in normalizing cholesterol esterification and lipoprotein particle structure.

Main Methods:

• Recombinant human LCAT (rhLCAT) was expressed.
• The ability of rhLCAT to correct lipoprotein profiles was tested in plasma from LCAT-deficient patients.
• Lipoprotein levels, cholesterol esterification, and particle sizes were analyzed before and after rhLCAT treatment.

Main Results:

• rhLCAT significantly reduced unesterified cholesterol by 30% and increased plasma cholesteryl esters by 210%.
• rhLCAT treatment led to an 89% increase in HDL-C levels.
• rhLCAT promoted the maturation of preβ-HDL into alpha-migrating particles and normalized LDL particle size.

Conclusions:

• Recombinant human LCAT effectively reverses key lipoprotein abnormalities associated with LCAT deficiency.
• rhLCAT demonstrates significant potential as a therapeutic agent for familial LCAT deficiency and fish-eye disease.
• This enzyme replacement strategy offers a promising avenue for managing these rare genetic lipid disorders.